Persistence of Resistant Variants in Hepatitis C Virus-Infected Patients Treated with the NS5A Replication Complex Inhibitor Daclatasvir

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2013-02-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.02494-12PMID 23403428PMCID PMC3632915
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

  2013cited by this paper
• Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders

  2012cited by this paper
• Preliminary study of two antiviral agents for hepatitis C genotype 1.

  2012cited by this paper
• Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.

  2012cited by this paper
• 1422 POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/− RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3

  2012cited by this paper
• Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5a replication complex inhibitor, BMS‐790052

  2012cited by this paper
• Hepatitis C Virus RNA Elimination and Development of Resistance in Replicon Cells Treated with BMS-790052

  2012influential reference
• Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS‐790052 in Humans: In Vitro and In Vivo Correlations

  2011influential reference
• Multiple ascending dose study of BMS‐790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1

  2011cited by this paper
• 1356 QUADRUPLE THERAPY WITH BMS-790052, BMS-650032 AND PEG-IFN/RBV FOR 24 WEEKS RESULTS IN 100% SVR12 IN HCV GENOTYPE 1 NULL RESPONDERS

  2011cited by this paper
• Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System

  2010influential reference
• A perspective on modelling hepatitis C virus infection

  2010cited by this paper
• Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

  2010influential reference
• Identification of Hepatitis C Virus NS5A Inhibitors

  2009cited by this paper
• Effect of Ribavirin on the Mutation Rate and Spectrum of Hepatitis C Virus In Vivo

  2009cited by this paper
• euHCVdb: the European hepatitis C virus database

  2006cited by this paper
• The European Hepatitis C Virus database

  2005cited by this paper
• Genetic diversity and evolution of hepatitis C virus--15 years on.

  2004cited by this paper

• Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure

  2024cites this paper
• Hepatitis C virus fitness can influence the extent of infection-mediated epigenetic modifications in the host cells

  2023cites this paper
• Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection

  2021influential citation
• Cost-effective green chromatographic method for the simultaneous determination of four commonly used direct-acting antiviral drugs in plasma and various pharmaceutical formulations

  2021cites this paper
• The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance

  2021cites this paper
• Population Disequilibrium as Promoter of Adaptive Explorations in Hepatitis C Virus

  2021cites this paper
• Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan

  2021cites this paper
• Retreatment of chronic hepatitis C virus genotype-4 patients after non-structural protein 5A inhibitors' failure: efficacy and safety of different regimens

  2020cites this paper
• Single-molecular real-time deep sequencing reveals the dynamics of multi-drug resistant haplotypes and structural variations in the hepatitis C virus genome

  2020cites this paper
• Sofosbuvir‐Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real‐life experience from the HEPATHER ANRS CO22 cohort

  2020cites this paper
• Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection

  2020cites this paper
• NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir

  2019cites this paper
• NS5A-P32 Deletion in Hepatitis C Genotype 1b Infection is the Most Refractory Treatment-Mediated Amino Acid Change Exhibiting Resistance to all NS5A Inhibitors

  2019cites this paper
• Impact of novel NS5A resistance-associated substitutions of hepatitis C virus detected in treatment-experienced patients

  2019cites this paper
• Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice

  2019cites this paper
• Evolution and persistence of resistance‐associated substitutions of hepatitis C virus after direct‐acting antiviral treatment failures

  2018cites this paper
• Nonstructural protein 5A/P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection

  2018cites this paper
• Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection

  2018cites this paper
• Characterization of HCV Resistance from a 3-Day Monotherapy Study of Voxilaprevir, a Novel Pangenotypic NS3/4A Protease Inhibitor

  2018cites this paper
• Challenge to overcome: Nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virus

  2018cites this paper
• No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.

  2018cites this paper
• Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse

  2018cites this paper
• Retreatment with sofosbuvir/ledipasvir with or without lead‐in interferon‐β injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapy

  2018cites this paper
• EASL Recommendations on Treatment of Hepatitis C 2018.

  2018cites this paper
• The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor‐naïve patients with chronic HCV genotype 1b infection in a real‐world cohort

  2018cites this paper
• Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015)

  2017cites this paper
• Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir.

  2017cites this paper
• Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil

  2017cites this paper
• Deep sequencing in the management of hepatitis virus infections.

  2017cites this paper
• In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir

  2017cites this paper
• Resistance to hepatitis C virus. Implications and therapeutic options.

  2017cites this paper
• EASL Recommendations on Treatment of Hepatitis C 2016.

  2017cites this paper
• Association between vitamin D deficiency and pre‐existing resistance‐associated hepatitis C virus NS5A variants

  2017cites this paper
• Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy

  2017cites this paper
• Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study

  2017cites this paper
• Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral–Experienced Patients With Hepatitis C

  2017cites this paper
• Personalized Medicine for Hepatitis C Virus

  2017cites this paper
• Treatment Effects and Resistance-Associated Variants of Sofosbuvir Regimen for Japanese Patients with Chronic Hepatitis C Virus Genotypes 1 and 2

  2017cites this paper
• Resistance to hepatitis C virus. Implications and therapeutic options

  2017cites this paper
• HCV Drug Resistance

  2017cites this paper
• Resistance to Direct-Acting Antiviral Agents in Treatment of Hepatitis C Virus Infections

  2017cites this paper
• Mixed genotype Hepatitis C virus infections: incidence in Scotland and methods for detection

  2017cites this paper
• Resistencias al virus de la hepatitis C. Implicaciones y posibilidades terapéuticas

  2017cites this paper
• Integrated pharmacokinetic/viral dynamic model for daclatasvir/asunaprevir in treatment of patients with genotype 1 chronic hepatitis C

  2017cites this paper
• Long-Term Persistence of HCV NS5A Resistance-Associated Substitutions after Treatment with the HCV NS5A Inhibitor, Ledipasvir, without Sofosbuvir

  2017cites this paper
• From current status to optimization of HCV treatment: Recommendations from an expert panel.

  2016cites this paper
• Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens.

  2016cites this paper
• Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir.

  2016cites this paper
• Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C

  2016cites this paper
• Geno2pheno[HCV] – A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents

  2016cites this paper
• Genotypic resistance testing of HCV – is there a clinical need?

  2016cites this paper
• Naturally Occurring HCV NS5A/B Inhibitor Resistance-Associated Mutations to Direct-Acting Antivirals

  2016cites this paper
• Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1

  2016cites this paper
• Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents

  2016cites this paper
• Manufacturer for United States

  2016cites this paper
• Preclinical and Clinical Resistance Profile of EDP-239, a Novel Hepatitis C Virus NS5A Inhibitor

  2016influential citation
• Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir‐containing regimen

  2016cites this paper
• Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time

  2016cites this paper
• Viral Variation and Response to Therapy

  2016cites this paper
• Safety and effi cacy of daclatasvir in the management of patients with chronic hepatitis C

  2016cites this paper
• 2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph.

  2016cites this paper
• SASLT Guidelines: Update in Treatment of Hepatitis C Virus Infection

  2016cites this paper
• Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection

  2016cites this paper
• The safety of daclatasvir for the treatment of hepatitis C

  2015cites this paper
• Recommendations on Treatment of Hepatitis C 2015

  2015cites this paper
• Mixed HCV infection and reinfection in people who inject drugs—impact on therapy

  2015cites this paper
• Resistance to direct-acting antiviral agents: clinical utility and significance

  2015cites this paper
• The Changing Face of Hepatitis C: Recent Advances on HCV Inhibitors Targeting NS5A

  2015cites this paper
• Virologic Tools for HCV Drug Resistance Testing

  2015cites this paper
• Daclatasvir for the treatment of chronic hepatitis C virus infection.

  2015cites this paper
• Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals

  2015cites this paper
• Naturally Occurring Dominant Drug Resistance Mutations Occur Infrequently in the Setting of Recently Acquired Hepatitis C

  2015cites this paper
• Causes of treatment failure for hepatitis C in the era of direct-acting antiviral therapy.

  2015cites this paper
• Design, synthesis and evaluation of novel anti-HCV molecules that deliver intracellularly three highly potent NS5A inhibitors.

  2015cites this paper
• EASL Recommendations on Treatment of Hepatitis C 2015.

  2015cites this paper
• Recommendations on Treatment of Hepatitis C 2018 q European Association for the Study of the Liver ⇑

  2015cites this paper
• Esmuyprobablequemásinvestigacióntengaunainfluenciaimportanteenlaconfianzaatribuidaalaestima - cióndelefectoyesprobablequepuedamodificarla. Todaestimacióndelefectoesincierta C

  2015cites this paper
• The role of HCV proteins on treatment outcomes

  2015cites this paper
• Quasispecies dynamics and treatment outcome during early hepatitis C infection in a cohort of HIV-infected men

  2015cites this paper
• New hepatitis C therapies: the toolbox, strategies, and challenges.

  2014cites this paper
• Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C

  2014cites this paper
• EASL recommendations on treatment of hepatitis C 2014.

  2014cites this paper
• Antiviral therapy of hepatitis C in 2014: do we need resistance testing?

  2014cites this paper
• In vitro Activity and Resistance Profile of Samatasvir , a Novel NS 5 A Replication Inhibitor 1 of Hepatitis C Virus 2

  2014cites this paper
• Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A.

  2014cites this paper
• In Vitro Activity and Resistance Profile of Samatasvir, a Novel NS5A Replication Inhibitor of Hepatitis C Virus

  2014cites this paper
• Comparison of Daclatasvir Resistance Barriers on NS5A from Hepatitis C Virus Genotypes 1 to 6: Implications for Cross-Genotype Activity

  2014cites this paper
• Asymmetric Binding to NS5A by Daclatasvir (BMS-790052) and Analogs Suggests Two Novel Modes of HCV Inhibition

  2014cites this paper
• Resistance Patterns Associated with HCV NS5A Inhibitors Provide Limited Insight into Drug Binding

  2014cites this paper
• Hepatitis C virus NS5A inhibitors and drug resistance mutations.

  2014cites this paper
• without Detectable Cross-Resistance Synergistic Anti-Hepatitis C Virus Activity NS5A Inhibitor Provides Additive to The Combination of Alisporivir plus an

  2014cites this paper
• Discovery and development of hepatitis C virus NS5A replication complex inhibitors.

  2014cites this paper
• Discovery of a novel class of potent HCV NS4B inhibitors: SAR studies on piperazinone derivatives.

  2014cites this paper
• A Quantitative High-Resolution Genetic Profile Rapidly Identifies Sequence Determinants of Hepatitis C Viral Fitness and Drug Sensitivity

  2014cites this paper
• Genetic barrier and variant fitness in hepatitis C as critical parameters for drug resistance development.

  2014cites this paper
• Daclatasvir for the treatment of hepatitis C virus infection

  2014cites this paper
• Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance.

  2014cites this paper
• Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus

  2014cites this paper
• Potency and Resistance Analysis of Hepatitis C Virus NS5B Polymerase Inhibitor BMS-791325 on All Major Genotypes

  2014cites this paper
• Importance of HCV genotype 1 subtypes for drug resistance and response to therapy

  2014cites this paper